Psychoactive drugs influence brain‑derived neurotrophic factor and neurotrophin 4/5 levels in the serum of colorectal cancer patients

Sarabi,Matthieu; Perraud,Aurélie; Mazouffre,Clément; Nouaille,Michelle; Jauberteau,Marie‑Odile; Mathonnet,Muriel

doi:10.3892/br.2016.801

Psychoactive drugs influence brain‑derived neurotrophic factor and neurotrophin 4/5 levels in the serum of colorectal cancer patients

Authors:
- Matthieu Sarabi
- Aurélie Perraud
- Clément Mazouffre
- Michelle Nouaille
- Marie‑Odile Jauberteau
- Muriel Mathonnet
View Affiliations

Affiliations: Department of Hepato‑Gastro‑Enterology, University of Limoges Teaching Hospital, F‑87042 Limoges Cedex, France, Department of Digestive, General and Endocrinal Surgery, University of Limoges Teaching Hospital, F‑87042 Limoges Cedex, France, Laboratory EA 3842, Cellular Homeostasis and Pathologies, Medicine and Pharmacy Faculties, University of Limoges, F‑87025 Limoges Cedex, France
Published online on: November 7, 2016 https://doi.org/10.3892/br.2016.801
Pages: 89-94

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Previous studies have reported the association between brain‑derived neurotrophic factor (BDNF) and tumor development in numerous cancers. However, the accurate implication of the two specific ligands of tropomyosin kinase B receptor, BDNF and neurotrophic factor 4 (NT4/5), has not been studied in colorectal cancer (CRC) patients. The present study investigated the significance of serum BDNF and the NT4/5 in association with the intake of psychoactive drugs in CRC patients. Soluble BDNF and NT4 in the serum were assessed by ELISA. Although no correlation of BDNF and NT4 with the CRC stage was identified, a positive correlation was found between NT4 and the intake of psychoactive drugs (P=0.0457). For BDNF, a correlation was found in particular with the intake of benzodiazepine (P=0.0221). As BDNF and NT4/5 are implicated in the response of psychoactive treatments applied to manage depression, which frequently occurs in cancer patients, they cannot be used as prognostic or diagnostic markers for CRC in these patients. However, high expression of BDNF and NT4 was significantly associated with better survival. Therefore, these NTs may be used as markers for monitoring depression or predicting survival in CRC patients.

View Figures

View References

1	Chao MV: Neurotrophins and their receptors: A convergence point for many signalling pathways. Nat Rev Neurosci. 4:299–309. 2003. View Article : Google Scholar : PubMed/NCBI
2	Rizos EN, Papadopoulou A, Laskos E, Michalopoulou PG, Kastania A, Vasilopoulos D, Katsafouros K and Lykouras L: Reduced serum BDNF levels in patients with chronic schizophrenic disorder in relapse, who were treated with typical or atypical antipsychotics. World J Biol Psychiatry. 11:251–255. 2010. View Article : Google Scholar : PubMed/NCBI
3	Martinotti G, Di Iorio G, Marini S, Ricci V, De Berardis D and Di Giannantonio M: Nerve growth factor and brain-derived neurotrophic factor concentrations in schizophrenia: A review. J Biol Regul Homeost Agents. 26:347–356. 2012.PubMed/NCBI
4	Huang TL and Hung YY: Lorazepam reduces the serum brain-derived neurotrophic factor level in schizophrenia patients with catatonia. Prog Neuropsychopharmacol Biol Psychiatry. 33:158–159. 2009. View Article : Google Scholar : PubMed/NCBI
5	Zuccato C, Marullo M, Vitali B, Tarditi A, Mariotti C, Valenza M, Lahiri N, Wild EJ, Sassone J, Ciammola A, et al: Brain-derived neurotrophic factor in patients with Huntington's disease. PLoS One. 6:e229662011. View Article : Google Scholar : PubMed/NCBI
6	Huang MC, Chen CH, Liu HC, Chen CC, Ho CC and Leu SJ: Differential patterns of serum brain-derived neurotrophic factor levels in alcoholic patients with and without delirium tremens during acute withdrawal. Alcohol Clin Exp Res. 35:126–131. 2011. View Article : Google Scholar : PubMed/NCBI
7	Ventriglia M, Zanardini R, Bonomini C, Zanetti O, Volpe D, Pasqualetti P, Gennarelli M and Bocchio-Chiavetto L: Serum brain-derived neurotrophic factor levels in different neurological diseases. Biomed Res Int. 2013.20901082
8	Tamaji A, Iwamoto K, Kawamura Y, Takahashi M, Ebe K, Kawano N, Kunimoto S, Aleksic B, Noda Y and Ozaki N: Differential effects of diazepam, tandospirone, and paroxetine on plasma brain-derived neurotrophic factor level under mental stress. Hum Psychopharmacol. 27:329–333. 2012. View Article : Google Scholar : PubMed/NCBI
9	Zhou L, Xiong J, Lim Y, Ruan Y, Huang C, Zhu Y, Zhong JH, Xiao Z and Zhou XF: Upregulation of blood proBDNF and its receptors in major depression. J Affect Disord. 150:776–784. 2013. View Article : Google Scholar : PubMed/NCBI
10	Kreinin A, Lisson S, Nesher E, Schneider J, Bergman J, Farhat K, Farah J, Lejbkowicz F, Yadid G, Raskin L, et al: Blood BDNF level is gender specific in severe depression. PLoS One. 10:e01276432015. View Article : Google Scholar : PubMed/NCBI
11	Chopin V, Lagadec C, Toillon RA and Le Bourhis X: Neurotrophin signaling in cancer stem cells. Cell Mol Life Sci. 73:1859–1870. 2016. View Article : Google Scholar : PubMed/NCBI
12	Akil H, Perraud A, Mélin C, Jauberteau M-O and Mathonnet M: Fine-tuning roles of endogenous brain-derived neurotrophic factor, TrkB and sortilin in colorectal cancer cell survival. PLoS One. 6:e250972011. View Article : Google Scholar : PubMed/NCBI
13	de Farias CB, Heinen TE, dos Santos RP, Abujamra AL, Schwartsmann G and Roesler R: BDNF/TrkB signaling protects HT-29 human colon cancer cells from EGFR inhibition. Biochem Biophys Res Commun. 425:328–332. 2012. View Article : Google Scholar : PubMed/NCBI
14	Tanaka K, Okugawa Y, Toiyama Y, Inoue Y, Saigusa S, Kawamura M, Araki T, Uchida K, Mohri Y and Kusunoki M: Brain-derived neurotrophic factor (BDNF)-induced tropomyosin-related kinase B (Trk B) signaling is a potential therapeutic target for peritoneal carcinomatosis arising from colorectal cancer. PLoS One. 9:e964102014. View Article : Google Scholar : PubMed/NCBI
15	Akil H, Perraud A, Jauberteau MO and Mathonnet M: Tropomyosin-related kinase B/brain derived-neurotrophic factor signaling pathway as a potential therapeutic target for colorectal cancer. World J Gastroenterol. 22:490–500. 2016. View Article : Google Scholar : PubMed/NCBI
16	Brierley GV, Priebe IK, Purins L, Fung KYC, Tabor B, Lockett T, Nice E, Gibbs P, Tie J, McMurrick P, et al: Serum concentrations of brain-derived neurotrophic factor (BDNF) are decreased in colorectal cancer patients. Cancer Biomark. 13:67–73. 2013.PubMed/NCBI
17	Yang ZF, Ho DW, Lau CK, Tam KH, Lam CT, Yu WC, Poon RTP and Fan ST: Significance of the serum brain-derived neurotrophic factor and platelets in hepatocellular carcinoma. Oncol Rep. 16:1237–1243. 2006.PubMed/NCBI
18	Jehn CF, Becker B, Flath B, Nogai H, Vuong L, Schmid P and Lüftner D: Neurocognitive function, brain-derived neurotrophic factor (BDNF) and IL-6 levels in cancer patients with depression. J Neuroimmunol. 287:88–92. 2015. View Article : Google Scholar : PubMed/NCBI
19	Saligan LN, Lukkahatai N, Holder G, Walitt B and Machado-Vieira R: Lower brain-derived neurotrophic factor levels associated with worsening fatigue in prostate cancer patients during repeated stress from radiation therapy. World J Biol Psychiatry. Mar 27–2015.(Epub ahead of print). View Article : Google Scholar : PubMed/NCBI
20	Kobayakawa M, Inagaki M, Fujimori M, Hamazaki K, Hamazaki T, Akechi T, Tsugane S, Nishiwaki Y, Goto K, Hashimoto K, et al: Serum brain-derived neurotrophic factor and antidepressant-naive major depression after lung cancer diagnosis. Jpn J Clin Oncol. 41:1233–1237. 2011. View Article : Google Scholar : PubMed/NCBI
21	Vanhecke E, Adriaenssens E, Verbeke S, Meignan S, Germain E, Berteaux N, Nurcombe V, Le Bourhis X and Hondermarck H: Brain-derived neurotrophic factor and neurotrophin-4/5 are expressed in breast cancer and can be targeted to inhibit tumor cell survival. Clin Cancer Res. 17:1741–1752. 2011. View Article : Google Scholar : PubMed/NCBI
22	Perraud A, Akil H, Nouaille M, Petit D, Labrousse F, Jauberteau MO and Mathonnet M: Implications of cleaved caspase 3 and AIF expression in colorectal cancer based on patient age. Oncol Rep. 27:1787–1793. 2012.PubMed/NCBI
23	Greene FL, Page DL, Fleming I, Fritz AG, Balch CM, Haller DG and Morrow M: Small Intestine (Lymphomas, carcinoid tumors, and visceral sarcomas are not included)AJCC (American Joint Committee on Cancer) Cancer Staging Manual. 6th. Springer-Verlag; New York: pp. 1132002
24	Wittekind C: Lymph nodes, tumour deposits, and TNM: Are we getting better? 7th edition of UICC 2010 TNM classification of malignant tumors. Strahlenther Onkol. 188:191–192. 2012.(In German). View Article : Google Scholar : PubMed/NCBI
25	Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
26	Hempstead BL: Brain-Derived Neurotrophic Factor: Three Ligands, Many Actions. Trans Am Clin Climatol Assoc. 126:9–19. 2015.PubMed/NCBI
27	Théry C: Exosomes: Secreted vesicles and intercellular communications. F1000 Biol Rep. 3:152011. View Article : Google Scholar : PubMed/NCBI